In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize shareholder value through a strategic transaction and ...

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while reviewing strategic options.

1 Day THRD -0.70% DJIA -1.51% Russell 2K -2.38% Health Care/Life Sciences -0.38% ...

Short interest in Third Harmonic Bio Inc (NASDAQ:THRD) increased during the last reporting period, rising from 3.57M to 3.66M. This put 16.24% of the company's publicly available shares short.